ECCO 2018
Read the full Report (pdf)
European Crohn’s and Colitis Organisation
14-17 February 2018
Vienna, Austria
Featured articles
CONTENTS
Online First
IBD diagnostics
Diagnostic techniques for IBD: the ECCO-ESGAR Guidelines
IBD disease patterns and genetics
Quiescent disease, characteristics and biomarker correlations
Central role of IL-23 in molecular resistance to anti-TNF therapy
Targeting early disease: lessons from rheumatoid arthritis
Integration of “omics” and potential for clinical practice
Novel treatment strategies
Combining new drugs with different mechanisms
Cobitolimod induces anti-inflammatory effects by balancing Th17/T-reg cell response
Early and significant effects with upadacitinib induction treatment
Vedolizumab induces endoscopic remission and healing in refractory CD
SHP647 is efficacious and well-tolerated in CD
Higher rates of remission and healing with vedolizumab vs TNF antagonist
Comparative effectiveness of vedolizumab and ustekinumab in CD
Efficacy and safety of biologics
Vedolizumab in anti-TNF-naïve IBD patients and safety profile
Long-term safety profile of adalimumab
Overall manageable safety profile of tofacitinib in long-term use
Oncology in IBD
Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD
Cancer risk in IBD associated with age and recent immunomodulator use
Shallow whole-genome sequencing predicts future cancer risk of LGD in UC
SLC12A2 potential marker of dysplasia associated to inflammation in UC
Significantly increased risk of CRC and/or HGD after appendectomy in UC
Surgery for IBD
